Hence, unlike ado-trastuzumab emtansine, correlations between tumour CD30 expression and tumour responses to brentuximab vedotin have not been found for other lymphomas with variable expression of CD30 (Fromm et al, 2012; Bartlett et al, 2013; Horwitz et al, 2014; Duvic et al, 2015; Jacobsen et al, 2015). This evidence concerns the gene TNFRSF8 and neoplasm.